Literature DB >> 28195341

Left ventricular systolic function is associated with sympathetic nervous activity and markers of inflammation in cirrhosis.

Raquel Yotti1, Cristina Ripoll2, Yolanda Benito1, Maria Vega Catalina2, Jaime Elízaga1, Diego Rincón2, Francisco Fernández-Avilés1, Javier Bermejo1, Rafael Bañares2.   

Abstract

An accurate evaluation of cardiac function in patients with cirrhosis remains a challenge. We used robust echocardiographic indices to characterize left ventricular (LV) systolic function and its relationship to activation of the sympathetic nervous system and inflammation in 59 patients with cirrhosis and 59 age-matched controls. Additionally, in 11 patients we withdrew beta-blockers and diuretics and used phenylephrine and albumin infusion to evaluate the response to acute afterload and preload changes (interventional substudy). Measures of systolic LV function such as the ejection intraventricular pressure difference (EIVPD) and the systolic strain rate were higher in patients with cirrhosis than in controls (median [1st-3rd quartile], 4.0 [3.1-5.1] versus 2.9 [2.4-3.6] mm Hg and -1.3 [-1.6 to -1.1] versus -1.2 [-1.6 to -1.1)] s-1 , respectively; P < 0.05 for both). EIVPD was related to the severity of liver disease (Model for End-Stage Liver Disease, rho = 0.45, P < 0.001), the degree of sympathetic nervous system activation (noradrenaline, rho = 0.26, P = 0.05; heart rate variability, rho = -0.43, P = 0.003), and treatment with beta-blockers (P = 0.001). In the interventional substudy, EIVPD was higher in patients with ascites (6.5 [5.4-8.5] versus 4.0 [3.9-5.1] mm Hg, P = 0.045). The decrease in EIVPD induced by phenylephrine was inversely related to baseline systolic function (P < 0.05) and associated with markers of systemic vasodilatation (nitric oxide, rho = -0.66, P = 0.06; diastolic blood pressure, rho = 0.68, P = 0.04) and inflammation (interleukin-1beta, rho = -0.80, P = 0.009).
CONCLUSION: LV systolic function is enhanced in cirrhosis due to augmented adrenergic tone and modulated by treatment with beta-blockers; acute afterload stress induces a deeper impairment of systolic function in patients with more advanced degrees of vasodilatation and inflammation; these changes in LV function related to cirrhosis can be assessed using robust echocardiographic methods. (Hepatology 2017;65:2019-2030).
© 2017 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28195341     DOI: 10.1002/hep.29104

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  8 in total

Review 1.  Cirrhosis-associated immune dysfunction.

Authors:  Agustín Albillos; Rosa Martin-Mateos; Schalk Van der Merwe; Reiner Wiest; Rajiv Jalan; Melchor Álvarez-Mon
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-10-26       Impact factor: 46.802

2.  Blunted cardiovascular effects of beta-blockers in patients with cirrhosis: Relation to severity?

Authors:  Puria Nabilou; Karen Vagner Danielsen; Nina Kimer; Jens Dahlgaard Hove; Flemming Bendtsen; Søren Møller
Journal:  PLoS One       Date:  2022-06-28       Impact factor: 3.752

Review 3.  Dysfunctional Immune Response in Acute-on-Chronic Liver Failure: It Takes Two to Tango.

Authors:  Rosa Martin-Mateos; Melchor Alvarez-Mon; Agustín Albillos
Journal:  Front Immunol       Date:  2019-05-01       Impact factor: 7.561

4.  Molecular Profiling of Decompensated Cirrhosis by a Novel MicroRNA Signature.

Authors:  Ana Garcia Garcia de Paredes; Nicolo Manicardi; Luis Tellez; Luis Ibañez; Felix Royo; Javier Bermejo; Carolina Blanco; Constantino Fondevila; Val Fernandez Lanza; Laura Garcia-Bermejo; Juan Manuel Falcon-Perez; Rafael Bañares; Jordi Gracia-Sancho; Agustin Albillos
Journal:  Hepatol Commun       Date:  2020-12-02

5.  High Interleukin-8 Levels Associated With Decreased Survival in Patients With Cirrhosis Following Transjugular Intrahepatic Portosystemic Shunt.

Authors:  Guofeng Liu; Xiaoze Wang; Tingting Yang; Yuling Yan; Tong Xiang; Li Yang; Xuefeng Luo
Journal:  Front Med (Lausanne)       Date:  2022-02-28

Review 6.  Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction.

Authors:  Cornelius Engelmann; Joan Clària; Gyongyi Szabo; Jaume Bosch; Mauro Bernardi
Journal:  J Hepatol       Date:  2021-07       Impact factor: 30.083

Review 7.  Cardiovascular dysfunction and liver transplantation.

Authors:  Hye-Mee Kwon; Gyu-Sam Hwang
Journal:  Korean J Anesthesiol       Date:  2018-04-02

8.  Haemodynamic changes in cirrhosis following terlipressin and induction of sepsis-a preclinical study using caval subtraction phase-contrast and cardiac MRI.

Authors:  Manil D Chouhan; Stuart A Taylor; Alan Bainbridge; Simon Walker-Samuel; Nathan Davies; Steve Halligan; Mark F Lythgoe; Rajeshwar P Mookerjee
Journal:  Eur Radiol       Date:  2020-10-12       Impact factor: 5.315

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.